Lipocine Phase 3 postpartum depression trial data for LPCN 1154 set for ASCP talk

• Lipocine set a Phase 3 clinical dataset for LPCN 1154, an oral brexanolone candidate for postpartum depression, for oral presentation at the American Society of Clinical Psychopharmacology annual meeting on May 26, 2026, with a related poster on May 27.
• The company framed the trial outcome as supportive of a rapid-acting, non-SSRI treatment that could stabilize symptoms within hours without intensive monitoring, positioning the drug for potential at-home use.
• Management highlighted tolerability as a key differentiator, citing low central nervous system depressant side effects without dissociation or hallucinations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA62123) on May 19, 2026, and is solely responsible for the information contained therein.